LUPELIC Trademark

Trademark Overview


On Monday, April 24, 2017, a trademark application was filed for LUPELIC with the United States Patent and Trademark Office. The USPTO has given the LUPELIC trademark a serial number of 87422482. The federal status of this trademark filing is REGISTERED as of Tuesday, September 25, 2018. This trademark is owned by Glaxo Group Limited. The LUPELIC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardi...
lupelic

General Information


Serial Number87422482
Word MarkLUPELIC
Filing DateMonday, April 24, 2017
Status700 - REGISTERED
Status DateTuesday, September 25, 2018
Registration Number5568177
Registration DateTuesday, September 25, 2018
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 5, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, May 1, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events


Event DateEvent Description
Friday, October 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 6, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 6, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, September 25, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, November 8, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, November 8, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 8, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, November 8, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 8, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, September 25, 2018REGISTERED-PRINCIPAL REGISTER
Monday, August 20, 20181(B) BASIS DELETED; PROCEED TO REGISTRATION
Tuesday, July 10, 2018NOTICE OF ALLOWANCE CANCELLED
Monday, August 20, 2018SOU EXTENSION 1 GRANTED
Monday, April 30, 2018SOU EXTENSION 1 FILED
Monday, August 20, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 10, 2018TEAS DELETE 1(B) BASIS RECEIVED
Friday, June 22, 2018NOTICE OF REVIVAL - E-MAILED
Friday, June 22, 2018SOU EXTENSION RECEIVED WITH TEAS PETITION
Friday, June 22, 2018PETITION TO REVIVE-GRANTED
Friday, June 22, 2018TEAS PETITION TO REVIVE RECEIVED
Monday, June 4, 2018ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, June 4, 2018ABANDONMENT - NO USE STATEMENT FILED
Monday, February 5, 2018ASSIGNED TO EXAMINER
Tuesday, October 31, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 5, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 5, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 16, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, July 26, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 19, 2017ASSIGNED TO EXAMINER
Monday, May 1, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 27, 2017NEW APPLICATION ENTERED